Digital transformation, green finance, and pharmaceutical affordability in China: a health economics perspective
Jingdong Huang, Xinyi Zhang · 2026
Read Digital transformation, green finance, and pharmaceutical affordability in China: a health economics perspective by Jingdong Huang, Xinyi Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13219370.txt.
Description
Jingdong Huang and Xinyi Zhang trace how digital change cuts drug financing costs in China in a 2026 paper. Drug prices carry financing costs through cost plus pricing, so cheaper finance can mean cheaper medicine. The team asks if going digital earns firms green credentials that unlock green finance.
They tracked 152 listed drug makers from 2016 to 2023. Digital steps raised the odds of green certification, and certification raised green finance access. Green finance then cut financing costs by a clear margin. The chain carried about a third of the total effect. Essential drug makers gained near twice the cost cut of other firms.
Catalog record
| CREATOR | Jingdong Huang, Xinyi Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 70 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |